Loading clinical trials...
Loading clinical trials...
Prognostic Value of Left Ventricular Mass Index in Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy
In this study, we aimed to analyze the association between left ventricular mass index and clinical outcomes to provide the potential indicator for worse survival.
This retrospective study aimed to determine the prognostic value of left ventricular mass index in predicting clinical outcomes, including all-cause death, new-onset or recurrent atrial fibrillation, and a composite endpoint of all-cause death, heart failure,permanent pacemaker implantation, new-onset or recurrent atrial fibrillation, and stroke.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Fuwai hospital
Beijing, Beijing Municipality, China
Start Date
June 1, 2011
Primary Completion Date
December 31, 2020
Completion Date
December 31, 2020
Last Updated
September 24, 2024
490
ACTUAL participants
Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)
OTHER
Lead Sponsor
Changrong Nie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions